Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant drop in short interest in May. As of May 29th, there was short interest totaling 26,405 shares, a drop of 86.1% from the May 14th total of 189,821 shares. Based on an average daily volume of 341,001 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Analyst Ratings Changes

Several brokerages recently weighed in on ALPMY. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 25th. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. Finally, Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Astellas Pharma Trading Down 1.5%

Shares of ALPMY stock opened at $13.29 on Wednesday. Astellas Pharma has a 1 year low of $9.11 and a 1 year high of $17.35. The firm has a fifty day moving average price of $14.98 and a 200-day moving average price of $14.60. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84. The company has a market cap of $24.05 billion, a price-to-earnings ratio of 12.37 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. The firm had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.28 billion. As a group, equities analysts predict that Astellas Pharma will post 1.34 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).